Nicholas Piramal
Piramal Lifesciences to invest Rs200 crore in drug researh
14 October 2009
Swati Piramal elected president of Assocham
10 October 2009
Piramal Life Sciences gets regulatory nod for studies on cancer molecule
13 May 2009
Piramal Healthcare to shut down UK unit
02 April 2009
LG, Hero Honda, Nicholas Piramal to focus on rural markets
17 January 2009
Piramal buys US-based Minrad to strengthen its position in anesthetics
24 December 2008
Piramal Healthcare and Pierre Fabre launch French dermo cosmetic range in India
23 July 2008
Piramal Healthcare acquires PlasmaSelect's polygeline product Haemaccel
03 July 2008
Nicholas Piramal buys two Khandelwal Laboratories brands for Rs116 crore
16 April 2008
Nicholas Piramal renamed Piramal Healthcare in group-wide rebranding exercise
11 March 2008
Nicholas Piramal Research in India's first public-private drug research project
22 February 2008
Nicholas Piramal R&D arm in $110-million new drug deal with Eli Lilly
15 February 2008
Nicholas Piramal launches hypertension product
07 February 2008
Nicholas Piramal buys Healthline's pharmaceuticals business
23 January 2008
Nicolas Piramal subsidiary Wellspring ties up with Hiranandani Hospitals
15 January 2008
Nicholas Piramal in JV with Japan's Arkray to market blood glucose monitoring products
19 December 2007
Nicholas Piramal's cyclin-dependent kinase inhibitors granted US product patent
11 December 2007
Nicholas Piramal in R&D collaboration with Merck & Co
19 November 2007
Nicholas Piramal to de-merge its new chemical entity research unit
31 August 2007
Nicholas Piramal''s new drug IND-P276 approved by US FDA
25 July 2007
Nicholas Piramal in tie-up for cancer, diabetes research
11 June 2007
Nicholas Piramal''s Wellspring acquires majority stake in Jankharia Imaging
05 January 2007
Nicholas Piramal signs R&D licensing agreements with UK''s Morvus Technology
27 October 2006
Nicholas Piramal acquires Boots Piramal Healthcare
03 October 2006
Nicholas Piramal to acquire Pfizer''s UK Facility
15 June 2006
Nicholas Piramal India Limited signs 10-year manufacturing and supply agreement
24 November 2005
AstraZeneca and Nicholas Piramal sign ''development and know-how'' agreement
27 October 2005
Nicholas Piramal acquires UK''s Avecia for £9.5 million
27 October 2005
Nicholas Piramal signs seven alliances
19 February 2005
Nicholas Piramal to take over UK''s Rhodia
18 December 2004
Nicholas Piramal finalises product in-licensing agreement with Ethypharm, France
18 August 2004
Nicholas Piramal in research collaboration with National Institute of Immunology
12 August 2004
Nicholas Piramal seals an in-licensing agreement with Genzyme Corporation for the Indian market
11 August 2004
Maneesh Nerurkar joins Nicholas Piramal as head of Formulations Research
31 March 2004
Nicholas Piramal, Indian Institute of Science to develop anti-fungal drugs
31 March 2004
Nicholas Piramal expands its Clinical Research facility
24 March 2004
World-renowned bioscientist, Dr. Saran Narang joins Nicholas Piramal Scientific Advisory Board
04 March 2004
Nicholas Piramal merges Canere Actives and Fine Chemicals Pvt. Ltd.
07 February 2004
Nicholas Piramal Q3 growth up 76.1 per cent
07 February 2004
Nicholas Piramal, SPPL debt programmes reaffirmed A1+
06 January 2004
Nicholas Piramal buys partner''s 50% stake in Sarabhai Piramal
26 December 2003
Nicholas Piramal enters into alliance with Biogen Idec, USA
02 December 2003
Nicholas Piramal follows MNC pharma companies'' strategy
03 October 2003
Nicholas Piramal rolls out growth plan; Maini, Chaudhuri on board
03 October 2003
FIIs, banks up holdings in Ranbaxy, Dr Reddy''s, Nicholas Piramal, Cipla
21 July 2003
GlaxoSmithKline announces a dividend of Rs 7 per equity share
13 March 2003
GlaxoSmithKline declares second interim dividend of 37%
21 December 2002
Glaxo SmithKline defers merger with Burroughs Wellcome
09 December 2002
Nicholas Piramal hikes its stake in JV by 9%
09 September 2002
Glaxo SmithKline to sue Novartis, Ranbaxy
23 August 2002
GlaxoSmithKline interim dividend at 33%
31 July 2002
Nicholas Piramal net profit at Rs 311 million
19 July 2002
Nicholas Piramal to focus on mega brands
18 June 2002
NPIL ropes in McKinsey for total integration
27 May 2002
GlaxoSmithkline to launch new products
12 March 2002
Nicholas Piramal''s new business strategy
04 March 2002
Pharma companies in talks with MIDC
13 December 2001
Nicholas Piramal to focus on biotech
13 November 2001
Nicholas Piramal-Rhone merger over
10 October 2001
Nicholas Piramal to launch drug for malaria
19 February 2000
About osteoarthritis
21 January 2000
Piramal drug for osteoarthritis
21 January 2000
Nicholas Piramal India Ltd.
15 December 1999
The corporate retailers
01 December 1999
Nicholas Piramal will gain from vitamin A price hike
10 November 1999
Vitamin A manufacturing process
10 November 1999
Novartis, Nicholas to buy Hoechst units
16 October 1999
Piramal-BUPA for one-stop healthcare
15 October 1999
Norton Healthcare ties up with Nicholas Piramal, RPG Life Sciences
06 August 1999
Nicholas Piramal buys four Eli Lilly brands
22 July 1999
Hoechst, Nicholas Piramal to co-market two products
01 July 1999
At the Crossroads of ''shoppertainment''
24 June 1999
Boots to sell Piramal ayurvedic products in Europe
12 May 1999
Nicholas Piramal plans separate IT business
11 May 1999
 search domain-b